Elisabet Borsheim
Concepts (342)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burns | 14 | 2022 | 164 | 3.780 |
Why?
| | Muscle, Skeletal | 24 | 2022 | 815 | 3.500 |
Why?
| | Insulin Resistance | 14 | 2026 | 282 | 3.320 |
Why?
| | Exercise | 20 | 2025 | 561 | 3.000 |
Why?
| | Muscle Proteins | 14 | 2022 | 350 | 2.540 |
Why?
| | Adiposity | 6 | 2024 | 147 | 1.940 |
Why?
| | Oxygen Consumption | 11 | 2025 | 201 | 1.810 |
Why?
| | Insulin | 16 | 2022 | 493 | 1.720 |
Why?
| | Body Mass Index | 12 | 2026 | 717 | 1.700 |
Why?
| | Mitochondria, Muscle | 5 | 2019 | 43 | 1.640 |
Why?
| | Body Composition | 8 | 2025 | 355 | 1.570 |
Why?
| | Pregnant Women | 4 | 2022 | 71 | 1.500 |
Why?
| | Diabetes, Gestational | 2 | 2022 | 52 | 1.310 |
Why?
| | Blood Glucose | 11 | 2026 | 490 | 1.220 |
Why?
| | Dietary Proteins | 3 | 2021 | 255 | 1.190 |
Why?
| | Energy Metabolism | 12 | 2025 | 324 | 1.180 |
Why?
| | Amino Acids | 8 | 2022 | 382 | 1.170 |
Why?
| | Obesity | 13 | 2025 | 1204 | 1.140 |
Why?
| | Phenylalanine | 7 | 2022 | 136 | 1.080 |
Why?
| | Sulfoxides | 3 | 2025 | 22 | 1.050 |
Why?
| | Isothiocyanates | 3 | 2025 | 21 | 1.050 |
Why?
| | Physical Fitness | 2 | 2025 | 56 | 1.040 |
Why?
| | Female | 54 | 2026 | 28782 | 1.020 |
Why?
| | Humans | 78 | 2026 | 53230 | 1.010 |
Why?
| | Proteins | 2 | 2025 | 351 | 0.990 |
Why?
| | Pregnancy | 16 | 2025 | 2608 | 0.990 |
Why?
| | Resistance Training | 4 | 2025 | 106 | 0.980 |
Why?
| | Alanine | 2 | 2025 | 43 | 0.980 |
Why?
| | Amino Acids, Essential | 5 | 2008 | 141 | 0.970 |
Why?
| | Triglycerides | 8 | 2022 | 171 | 0.940 |
Why?
| | Child | 20 | 2025 | 7379 | 0.920 |
Why?
| | Male | 53 | 2026 | 27435 | 0.880 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2025 | 71 | 0.880 |
Why?
| | Liver | 7 | 2026 | 1150 | 0.870 |
Why?
| | Postural Balance | 1 | 2025 | 59 | 0.850 |
Why?
| | Child, Preschool | 15 | 2024 | 4162 | 0.840 |
Why?
| | Leptin | 2 | 2022 | 151 | 0.840 |
Why?
| | NF-E2-Related Factor 2 | 2 | 2021 | 47 | 0.820 |
Why?
| | Oxidative Stress | 4 | 2025 | 819 | 0.810 |
Why?
| | Adipose Tissue | 4 | 2019 | 210 | 0.810 |
Why?
| | Eating | 2 | 2021 | 159 | 0.800 |
Why?
| | Amino Acids, Branched-Chain | 2 | 2021 | 43 | 0.780 |
Why?
| | Maternal Nutritional Physiological Phenomena | 2 | 2020 | 64 | 0.730 |
Why?
| | Threonine | 1 | 2022 | 15 | 0.730 |
Why?
| | Zinc | 1 | 2022 | 56 | 0.710 |
Why?
| | Parents | 2 | 2022 | 341 | 0.690 |
Why?
| | Breast Feeding | 2 | 2022 | 203 | 0.680 |
Why?
| | Nutrition Policy | 1 | 2021 | 40 | 0.680 |
Why?
| | Nutritional Requirements | 1 | 2021 | 70 | 0.660 |
Why?
| | DNA Methylation | 2 | 2022 | 592 | 0.650 |
Why?
| | Adrenergic beta-Antagonists | 3 | 2014 | 108 | 0.650 |
Why?
| | Adult | 31 | 2026 | 14534 | 0.630 |
Why?
| | Health Behavior | 1 | 2022 | 261 | 0.620 |
Why?
| | Blood Pressure | 2 | 2021 | 518 | 0.610 |
Why?
| | Indocyanine Green | 2 | 2019 | 29 | 0.610 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2025 | 591 | 0.610 |
Why?
| | Blood Cells | 1 | 2019 | 37 | 0.600 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2019 | 64 | 0.570 |
Why?
| | Adipose Tissue, Brown | 5 | 2016 | 45 | 0.550 |
Why?
| | Arginine | 4 | 2022 | 178 | 0.530 |
Why?
| | Leucine | 6 | 2021 | 114 | 0.510 |
Why?
| | Adolescent | 16 | 2026 | 6907 | 0.510 |
Why?
| | Weight Gain | 4 | 2022 | 245 | 0.500 |
Why?
| | Muscle Strength | 3 | 2025 | 132 | 0.490 |
Why?
| | Autonomic Nervous System | 1 | 2016 | 60 | 0.470 |
Why?
| | Electron Transport Complex II | 1 | 2015 | 7 | 0.460 |
Why?
| | Dietary Supplements | 8 | 2025 | 479 | 0.460 |
Why?
| | Specimen Handling | 2 | 2026 | 63 | 0.460 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 21 | 0.460 |
Why?
| | Hypoglycemic Agents | 2 | 2014 | 227 | 0.450 |
Why?
| | Oxidative Phosphorylation | 1 | 2015 | 48 | 0.450 |
Why?
| | Oxidation-Reduction | 6 | 2021 | 333 | 0.450 |
Why?
| | Metabolic Diseases | 3 | 2025 | 47 | 0.430 |
Why?
| | Androgens | 1 | 2014 | 70 | 0.430 |
Why?
| | Anabolic Agents | 1 | 2014 | 41 | 0.430 |
Why?
| | Time Factors | 12 | 2026 | 2991 | 0.420 |
Why?
| | Down-Regulation | 1 | 2015 | 344 | 0.420 |
Why?
| | Muscles | 1 | 2014 | 110 | 0.410 |
Why?
| | Dietary Carbohydrates | 2 | 2004 | 91 | 0.400 |
Why?
| | Diphosphonates | 1 | 2014 | 92 | 0.400 |
Why?
| | Fatty Liver | 2 | 2026 | 145 | 0.400 |
Why?
| | Fibroblast Growth Factors | 2 | 2026 | 52 | 0.390 |
Why?
| | Physical Exertion | 3 | 1998 | 45 | 0.390 |
Why?
| | Cohort Studies | 5 | 2021 | 1557 | 0.380 |
Why?
| | Fatty Acids, Nonesterified | 4 | 2020 | 39 | 0.380 |
Why?
| | Aging | 3 | 2015 | 714 | 0.380 |
Why?
| | Milk, Human | 2 | 2026 | 122 | 0.370 |
Why?
| | Mitochondria | 4 | 2025 | 446 | 0.370 |
Why?
| | Exercise Therapy | 3 | 2025 | 105 | 0.350 |
Why?
| | Case-Control Studies | 5 | 2021 | 1212 | 0.350 |
Why?
| | Animals | 15 | 2025 | 13526 | 0.350 |
Why?
| | Kinetics | 5 | 2025 | 607 | 0.350 |
Why?
| | Deuterium | 4 | 2025 | 47 | 0.340 |
Why?
| | Adiponectin | 2 | 2021 | 47 | 0.340 |
Why?
| | Reproducibility of Results | 4 | 2025 | 1219 | 0.330 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 501 | 0.330 |
Why?
| | Blood Platelets | 2 | 2025 | 247 | 0.330 |
Why?
| | MicroRNAs | 3 | 2026 | 397 | 0.320 |
Why?
| | Pregnancy Complications | 2 | 2025 | 406 | 0.320 |
Why?
| | Homeostasis | 3 | 2021 | 209 | 0.320 |
Why?
| | Nitrogen Isotopes | 3 | 2022 | 39 | 0.310 |
Why?
| | Glucose | 3 | 2023 | 361 | 0.310 |
Why?
| | Lipid Metabolism | 3 | 2016 | 189 | 0.310 |
Why?
| | Absorptiometry, Photon | 3 | 2025 | 160 | 0.310 |
Why?
| | Glucose Intolerance | 3 | 2020 | 27 | 0.310 |
Why?
| | Receptors, Adrenergic, beta | 2 | 2000 | 44 | 0.300 |
Why?
| | Anthropometry | 3 | 2025 | 101 | 0.300 |
Why?
| | Longitudinal Studies | 4 | 2024 | 774 | 0.290 |
Why?
| | Hypertriglyceridemia | 1 | 2008 | 18 | 0.290 |
Why?
| | Fatty Acids | 3 | 2004 | 154 | 0.280 |
Why?
| | Palmitic Acid | 2 | 2006 | 22 | 0.260 |
Why?
| | Oleic Acid | 1 | 2006 | 5 | 0.250 |
Why?
| | Young Adult | 8 | 2024 | 4511 | 0.250 |
Why?
| | Nitrogen | 2 | 2021 | 70 | 0.250 |
Why?
| | Lipids | 3 | 2023 | 163 | 0.240 |
Why?
| | RNA Stability | 1 | 2026 | 29 | 0.240 |
Why?
| | Carnitine | 2 | 2022 | 67 | 0.230 |
Why?
| | Brain Injuries | 1 | 2007 | 160 | 0.230 |
Why?
| | Protein Biosynthesis | 4 | 2017 | 268 | 0.230 |
Why?
| | Deuterium Oxide | 1 | 2025 | 10 | 0.230 |
Why?
| | Accelerometry | 1 | 2025 | 14 | 0.220 |
Why?
| | Tryptophan | 1 | 2025 | 89 | 0.220 |
Why?
| | Infant | 4 | 2021 | 3805 | 0.220 |
Why?
| | RNA | 1 | 2026 | 173 | 0.220 |
Why?
| | Renal Dialysis | 2 | 2005 | 196 | 0.220 |
Why?
| | Rats | 3 | 2025 | 3162 | 0.210 |
Why?
| | Weight Lifting | 1 | 2004 | 29 | 0.210 |
Why?
| | Adaptation, Physiological | 2 | 2014 | 109 | 0.210 |
Why?
| | Pregnancy Outcome | 1 | 2025 | 231 | 0.210 |
Why?
| | Milk Proteins | 1 | 2004 | 77 | 0.200 |
Why?
| | Propranolol | 4 | 2014 | 77 | 0.200 |
Why?
| | Physical Conditioning, Animal | 1 | 2023 | 67 | 0.200 |
Why?
| | Inflammation | 2 | 2025 | 652 | 0.190 |
Why?
| | Isoflavones | 1 | 2023 | 88 | 0.190 |
Why?
| | Cross-Sectional Studies | 2 | 2026 | 1723 | 0.190 |
Why?
| | Palmitates | 1 | 2022 | 28 | 0.190 |
Why?
| | Lipolysis | 2 | 2012 | 11 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 630 | 0.180 |
Why?
| | Isoleucine | 1 | 2021 | 27 | 0.180 |
Why?
| | Aged | 5 | 2022 | 10429 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 1 | 2022 | 122 | 0.180 |
Why?
| | Cattle | 1 | 2022 | 207 | 0.180 |
Why?
| | Skin Aging | 1 | 2021 | 11 | 0.170 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 128 | 0.170 |
Why?
| | Alanine Transaminase | 1 | 2021 | 118 | 0.170 |
Why?
| | Organ Size | 2 | 2019 | 226 | 0.170 |
Why?
| | Gestational Age | 2 | 2019 | 394 | 0.170 |
Why?
| | Swine | 3 | 2015 | 440 | 0.170 |
Why?
| | Biopsy | 3 | 2014 | 600 | 0.170 |
Why?
| | Maternal-Fetal Exchange | 1 | 2020 | 48 | 0.160 |
Why?
| | Hydrocortisone | 5 | 2020 | 113 | 0.160 |
Why?
| | Meals | 1 | 2020 | 65 | 0.150 |
Why?
| | Physical Endurance | 3 | 2004 | 35 | 0.150 |
Why?
| | Oxidative Phosphorylation Coupling Factors | 1 | 2019 | 6 | 0.150 |
Why?
| | Sarcopenia | 1 | 2020 | 100 | 0.150 |
Why?
| | Burn Units | 1 | 2019 | 9 | 0.150 |
Why?
| | Schools | 1 | 2020 | 185 | 0.150 |
Why?
| | Lipoproteins, VLDL | 1 | 1999 | 8 | 0.150 |
Why?
| | Liver Failure | 1 | 2019 | 21 | 0.150 |
Why?
| | Models, Biological | 3 | 2019 | 737 | 0.150 |
Why?
| | Monocytes | 1 | 2019 | 126 | 0.140 |
Why?
| | Adipose Tissue, White | 2 | 2016 | 35 | 0.140 |
Why?
| | Epigenesis, Genetic | 1 | 2022 | 412 | 0.140 |
Why?
| | Feeding Behavior | 1 | 2020 | 195 | 0.140 |
Why?
| | Receptors, Adrenergic | 1 | 1998 | 14 | 0.140 |
Why?
| | Sympathetic Nervous System | 1 | 1998 | 17 | 0.140 |
Why?
| | Age Factors | 2 | 2019 | 1136 | 0.140 |
Why?
| | Hepatocytes | 1 | 2019 | 188 | 0.140 |
Why?
| | Heart Rate | 5 | 2007 | 314 | 0.140 |
Why?
| | Cold Temperature | 2 | 2016 | 54 | 0.140 |
Why?
| | Arkansas | 2 | 2020 | 2068 | 0.140 |
Why?
| | Mitochondrial Proteins | 2 | 2015 | 90 | 0.130 |
Why?
| | Ion Channels | 2 | 2015 | 70 | 0.130 |
Why?
| | Risk Factors | 3 | 2024 | 4017 | 0.130 |
Why?
| | Urea | 2 | 2010 | 80 | 0.130 |
Why?
| | Patient Discharge | 1 | 2019 | 325 | 0.130 |
Why?
| | Carbon Isotopes | 4 | 2005 | 73 | 0.120 |
Why?
| | Hypertension | 1 | 2021 | 554 | 0.120 |
Why?
| | Thermogenesis | 2 | 2014 | 31 | 0.120 |
Why?
| | Carbohydrate Metabolism | 1 | 2016 | 25 | 0.120 |
Why?
| | Human Growth Hormone | 2 | 2014 | 49 | 0.120 |
Why?
| | Treatment Outcome | 3 | 2014 | 5595 | 0.120 |
Why?
| | Exercise Test | 3 | 2025 | 137 | 0.120 |
Why?
| | Proton Ionophores | 1 | 2015 | 3 | 0.120 |
Why?
| | Uncoupling Agents | 1 | 2015 | 5 | 0.120 |
Why?
| | Cell Respiration | 3 | 2025 | 49 | 0.120 |
Why?
| | Carbonyl Cyanide m-Chlorophenyl Hydrazone | 1 | 2015 | 5 | 0.120 |
Why?
| | Oligomycins | 1 | 2015 | 8 | 0.120 |
Why?
| | Myofibrils | 1 | 2015 | 20 | 0.120 |
Why?
| | Ethanol | 1 | 1998 | 338 | 0.110 |
Why?
| | Infusions, Intravenous | 2 | 2013 | 211 | 0.110 |
Why?
| | Hyperinsulinism | 1 | 2015 | 30 | 0.110 |
Why?
| | Nutritional Support | 1 | 2015 | 31 | 0.110 |
Why?
| | Oxandrolone | 1 | 2014 | 10 | 0.110 |
Why?
| | Quadriceps Muscle | 1 | 2015 | 47 | 0.110 |
Why?
| | Body Surface Area | 1 | 2014 | 26 | 0.110 |
Why?
| | Ascorbic Acid | 1 | 2014 | 26 | 0.110 |
Why?
| | Vitamins | 1 | 2014 | 64 | 0.110 |
Why?
| | Placebos | 1 | 2014 | 80 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 934 | 0.110 |
Why?
| | Stress, Physiological | 1 | 2015 | 184 | 0.110 |
Why?
| | Testosterone | 1 | 2014 | 142 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 127 | 0.110 |
Why?
| | Vitamin E | 1 | 2014 | 76 | 0.100 |
Why?
| | Cross-Over Studies | 3 | 2020 | 241 | 0.100 |
Why?
| | Mitochondrial Diseases | 1 | 2014 | 45 | 0.100 |
Why?
| | Area Under Curve | 2 | 2004 | 185 | 0.100 |
Why?
| | Mice | 2 | 2021 | 5982 | 0.100 |
Why?
| | Signal Transduction | 1 | 2020 | 1748 | 0.100 |
Why?
| | Metformin | 1 | 2014 | 84 | 0.100 |
Why?
| | Norepinephrine | 3 | 2000 | 106 | 0.100 |
Why?
| | Recombinant Proteins | 1 | 2014 | 489 | 0.100 |
Why?
| | Middle Aged | 5 | 2025 | 13419 | 0.100 |
Why?
| | Cachexia | 1 | 2013 | 28 | 0.100 |
Why?
| | Muscle Strength Dynamometer | 2 | 2014 | 12 | 0.100 |
Why?
| | Skin | 1 | 2015 | 419 | 0.090 |
Why?
| | Fenofibrate | 1 | 2012 | 17 | 0.090 |
Why?
| | Rest | 2 | 2014 | 60 | 0.090 |
Why?
| | PPAR alpha | 1 | 2012 | 61 | 0.090 |
Why?
| | Hyperglycemia | 1 | 2012 | 90 | 0.090 |
Why?
| | Health Status | 1 | 2013 | 306 | 0.090 |
Why?
| | Antioxidants | 2 | 2025 | 264 | 0.090 |
Why?
| | Diet | 2 | 2024 | 610 | 0.090 |
Why?
| | United States | 1 | 2021 | 5409 | 0.080 |
Why?
| | Extracellular Fluid | 2 | 2009 | 14 | 0.080 |
Why?
| | Isoproterenol | 2 | 2000 | 55 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2017 | 729 | 0.080 |
Why?
| | Hemodilution | 1 | 2009 | 7 | 0.070 |
Why?
| | Cholesterol, VLDL | 1 | 2008 | 3 | 0.070 |
Why?
| | Prospective Studies | 1 | 2015 | 2411 | 0.070 |
Why?
| | Isotonic Solutions | 1 | 2009 | 19 | 0.070 |
Why?
| | Regional Blood Flow | 2 | 2000 | 112 | 0.070 |
Why?
| | Forearm | 1 | 2009 | 30 | 0.070 |
Why?
| | Cholesterol | 1 | 2008 | 161 | 0.070 |
Why?
| | Anesthesia, Inhalation | 1 | 2007 | 12 | 0.070 |
Why?
| | Isoflurane | 1 | 2007 | 16 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2015 | 3494 | 0.070 |
Why?
| | Reference Values | 2 | 1998 | 311 | 0.070 |
Why?
| | Sodium Chloride | 1 | 2007 | 53 | 0.070 |
Why?
| | Anesthetics, Inhalation | 1 | 2007 | 34 | 0.070 |
Why?
| | Gait | 1 | 2008 | 90 | 0.060 |
Why?
| | Lower Extremity | 1 | 2008 | 103 | 0.060 |
Why?
| | Beverages | 1 | 2007 | 58 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 2 | 2026 | 1583 | 0.060 |
Why?
| | Epinephrine | 2 | 1998 | 92 | 0.060 |
Why?
| | Carbon Dioxide | 1 | 2006 | 97 | 0.060 |
Why?
| | Intracellular Fluid | 1 | 2005 | 11 | 0.060 |
Why?
| | Microdialysis | 1 | 2005 | 18 | 0.060 |
Why?
| | Buffers | 1 | 2025 | 12 | 0.060 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 64 | 0.060 |
Why?
| | Creatine | 1 | 2004 | 39 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2005 | 333 | 0.050 |
Why?
| | Fathers | 1 | 2024 | 27 | 0.050 |
Why?
| | Skiing | 1 | 2004 | 3 | 0.050 |
Why?
| | Endocrine System | 1 | 2004 | 16 | 0.050 |
Why?
| | Immune System | 1 | 2004 | 41 | 0.050 |
Why?
| | Sex Factors | 2 | 2004 | 747 | 0.050 |
Why?
| | Rats, Zucker | 1 | 2023 | 73 | 0.050 |
Why?
| | Caseins | 1 | 2023 | 78 | 0.050 |
Why?
| | Eukaryotic Initiation Factor-2B | 1 | 2003 | 5 | 0.050 |
Why?
| | Physical Education and Training | 1 | 2003 | 23 | 0.050 |
Why?
| | Catecholamines | 2 | 2004 | 44 | 0.050 |
Why?
| | Sports | 1 | 2003 | 45 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2020 | 2913 | 0.050 |
Why?
| | Soybean Proteins | 1 | 2023 | 167 | 0.050 |
Why?
| | Mothers | 1 | 2024 | 269 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 232 | 0.040 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2021 | 88 | 0.040 |
Why?
| | Proteomics | 1 | 2023 | 336 | 0.040 |
Why?
| | Hydralazine | 1 | 2000 | 3 | 0.040 |
Why?
| | Body Fat Distribution | 1 | 2020 | 10 | 0.040 |
Why?
| | Glycerol | 1 | 2000 | 19 | 0.040 |
Why?
| | Polysomnography | 1 | 2020 | 76 | 0.040 |
Why?
| | Depression | 1 | 2025 | 621 | 0.040 |
Why?
| | Osmolar Concentration | 2 | 2003 | 61 | 0.040 |
Why?
| | Thiobarbituric Acid Reactive Substances | 1 | 1999 | 10 | 0.040 |
Why?
| | Language | 1 | 2020 | 147 | 0.040 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2019 | 141 | 0.040 |
Why?
| | Plethysmography | 1 | 2019 | 43 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 421 | 0.040 |
Why?
| | Sleep | 1 | 2020 | 195 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2020 | 411 | 0.040 |
Why?
| | Adrenergic beta-Agonists | 1 | 1998 | 39 | 0.040 |
Why?
| | Bicycling | 1 | 1998 | 29 | 0.040 |
Why?
| | Community-Based Participatory Research | 1 | 2020 | 203 | 0.040 |
Why?
| | Atenolol | 1 | 1998 | 13 | 0.040 |
Why?
| | Xenon Radioisotopes | 1 | 1998 | 2 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 726 | 0.030 |
Why?
| | Carbon Radioisotopes | 1 | 1998 | 55 | 0.030 |
Why?
| | Hemoglobins | 2 | 2009 | 114 | 0.030 |
Why?
| | Lipoproteins | 1 | 2016 | 41 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 1925 | 0.030 |
Why?
| | Neck | 1 | 2016 | 97 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2016 | 310 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 287 | 0.030 |
Why?
| | Isometric Contraction | 1 | 2014 | 20 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 16 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2014 | 46 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2014 | 47 | 0.030 |
Why?
| | Torque | 1 | 2014 | 16 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 598 | 0.030 |
Why?
| | Glucose Clamp Technique | 1 | 2014 | 15 | 0.030 |
Why?
| | Calorimetry, Indirect | 1 | 2014 | 25 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2014 | 61 | 0.030 |
Why?
| | Basal Metabolism | 1 | 2014 | 32 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 92 | 0.030 |
Why?
| | Demography | 1 | 2014 | 91 | 0.030 |
Why?
| | Prognosis | 1 | 2019 | 2118 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2019 | 2318 | 0.030 |
Why?
| | Recovery of Function | 1 | 2014 | 203 | 0.030 |
Why?
| | Survivors | 1 | 2014 | 120 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2014 | 198 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2014 | 182 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2014 | 239 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2014 | 298 | 0.020 |
Why?
| | Leg | 2 | 2003 | 123 | 0.020 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2012 | 16 | 0.020 |
Why?
| | Hypolipidemic Agents | 1 | 2012 | 30 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2014 | 1049 | 0.020 |
Why?
| | Plasma Volume | 1 | 2009 | 3 | 0.020 |
Why?
| | Capillary Permeability | 1 | 2009 | 29 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 1180 | 0.020 |
Why?
| | Radial Artery | 1 | 2009 | 34 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2009 | 174 | 0.020 |
Why?
| | Veins | 1 | 2009 | 74 | 0.020 |
Why?
| | Population | 1 | 2007 | 8 | 0.020 |
Why?
| | Cardiac Output | 1 | 2007 | 30 | 0.020 |
Why?
| | Coloring Agents | 1 | 2007 | 65 | 0.020 |
Why?
| | Hormones | 1 | 2007 | 58 | 0.020 |
Why?
| | Palmitoylcarnitine | 1 | 2005 | 7 | 0.010 |
Why?
| | Methods | 1 | 2005 | 53 | 0.010 |
Why?
| | Reference Standards | 1 | 2005 | 52 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2007 | 204 | 0.010 |
Why?
| | Body Weight | 1 | 2007 | 524 | 0.010 |
Why?
| | Rabbits | 1 | 2005 | 372 | 0.010 |
Why?
| | Fluorocarbons | 1 | 2005 | 65 | 0.010 |
Why?
| | Granulocytes | 1 | 2004 | 27 | 0.010 |
Why?
| | Albumins | 1 | 2004 | 29 | 0.010 |
Why?
| | Task Performance and Analysis | 1 | 2004 | 52 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 2002 | 99 | 0.010 |
Why?
| | Valine | 1 | 2002 | 58 | 0.010 |
Why?
| | Glycine | 1 | 2002 | 75 | 0.010 |
Why?
|
|
Borsheim's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|